Steven Tsai, MD
Hematology & Oncology · Santa Monica, CANPI 1922341205
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,231 of the $1,642 with a category attached, or 75.0%. Adaptive Biotechnologies Corporation accounts for 86.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $1,440 and has fallen 89.8% since, to $147 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 12 payments — averaging $136.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Adaptive Biotechnologies Corporation$1K
- Seagen Inc.$93
- Incyte Corporation$56
- Daiichi Sankyo Inc.$52
- Beone Medicines USA, Inc.$26
Across 86 payments — averaging $3095.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$176K
- Seres Therapeutics, Inc.$52K
- Bristol Myers Squibb$27K
- National Marrow Donor Program$11K
What the payments were for
- Travel & lodging$1,23175%
- Food & beverage$31819%
- Education$936%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Adaptive Biotechnologies Corporation | 7 | $1,416 |
| Seagen Inc. | 1 | $93 |
| Incyte Corporation | 1 | $56 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Beone Medicines USA, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- clonoSEQ$1,179
How this compares
$1,642 in reported general payments places this provider in the 40th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OjjaaraMomelotinib Dihydrochloride | 17 | $827,253 |
| XospataGilteritinib Fumarate | 24 | $446,077 |
| IclusigPonatinib Hcl | 13 | $379,671 |
| VenclextaVenetoclax | 29 | $244,568 |
| RevlimidLenalidomide | 19 | $236,933 |
| CresembaIsavuconazonium Sulfate | 17 | $149,943 |
| EliquisApixaban | 21 | $32,145 |
| XareltoRivaroxaban | 32 | $26,338 |
| Posaconazole | 11 | $23,942 |
| Acyclovir | 51 | $1,642 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $432 |
| Hydroxyurea | 14 | $420 |
| Levofloxacin | 12 | $162 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Santa Monica
- Omid HamidSanta Monica$809K
- Richard FinnSanta Monica$784K
- Zev WainbergSanta Monica$761K
- Saeed SadeghiSanta Monica$696K
- Aditya BardiaSanta Monica$593K
- Steven OdaySanta Monica$270K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.